Molbio Diagnostics Secures ₹281 Cr from Global Giants as IPO Looms Amid Tech Expansion Plans

Molbio Diagnostics Secures ₹281 Cr from Global Giants as IPO Looms Amid Tech Expansion Plans​

Point-of-care diagnostics firm, Molbio Diagnostics Ltd., has secured a significant tranche of capital, raising ₹281.5 crore from anchor investors ahead of its Initial Public Offering (IPO).The company allotted 34.88 lakh equity shares to 33 diverse anchor institutions at the upper end of the price band, which was set at ₹807 apiece, as disclosed via a circular uploaded on the BSE website.

Strong Anchor Investor Participation Signals Market Confidence​

The successful fundraising highlights strong confidence from institutional players in Molbio's technology and market positioning.Among the prominent anchor investors include global heavyweights such as Goldman Sachs and BlackRock Global Funds, alongside domestic entities like ICICI Prudential Mutual Fund, Kotak Mutual Fund, and Tata Mutual Fund.

Domestic mutual funds demonstrated overwhelming support for the company.These funds secured 23.54 lakh shares, which accounts for 67.51 per cent of the total anchor book through 19 different schemes offered by nine fund houses.

IPO Structure Details: Pricing and Subscription Window​

The IPO features a price band ranging from ₹768 to ₹807 per share.The public subscription phase is scheduled to commence on August 10 and conclude on August 12, giving investors a clear timeline for participation.

The initial share sale is conservatively estimated to generate between ₹904 crore at the lower end of the price band and ₹940 crore at the upper end. The IPO structure includes both a fresh issue of shares, valued up to ₹200 crore, and an Offer for Sale (OFS) comprising 91.66 lakh equity shares held by existing shareholders.

Strategic Fund Allocation Drives Future Growth​

Molbio Diagnostics has clearly outlined the use of proceeds intended to fuel its future expansion and infrastructure needs.The company plans to allocate ₹106 crore from the fresh issue proceeds specifically for capital expenditure related to setting up an R&D facility, a Centre of Excellence, and connected office space.

Further, another ₹72 crore is earmarked for the purchase of essential plant, machinery, and equipment designated for its operational units in Goa Unit I, Goa Unit II, and Visakhapatnam unit.The remaining funds will be deployed for general corporate purposes as outlined in the company filings.

Company Profile and Market Potential​

Founded in 2000, Molbio Diagnostics operates as a key player in point-of-care diagnostics, providing molecular testing services for over 30 diseases.This includes critical infections such as COVID, HIV, HPV, Tuberculosis, and Hepatitis B and C.

The cornerstone of the company's offering is its 'Truenat' platform, which is a battery-operated polymerase chain reaction (PCR) system patented in more than 100 countries. This platform enables decentralized diagnosis within an hour, making it ideal for resource-limited settings.

Financial Performance and Listing Details​

The firm maintains multiple manufacturing presences across India, with facilities located in Goa, Bengaluru, Visakhapatnam, and Pune.As of March 31, 2026, Molbio's installed capacity stood at 5,400 devices per annum and an annual production target of 3.9 crore Truenat test kits.

Financially, the company reported a revenue from operations of ₹1,445 crore in fiscal 2026 and a profit of ₹164 crore during that period.The stock is scheduled to be listed on both the BSE and NSE on August 17, with Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors serving as the book-running lead managers.